At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 21 enrolled
Drug / intervention
GB-102drug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 2a Multicenter Study Evaluating the Safety, Tolerability, and Pharmacodynamics of Sunitinib Malate Depot Formulation (GB-102) in Subjects With Diabetic Macular Edema (DME) and Retinal Vein Occlusion (RVO)
In Brief
A Phase 2 clinical trial evaluating GB-102 for Diabetic Macular Edema and Retina Vein Occlusion. Completed, enrolled 21 participants across 6 sites.
Detailed Summary
Phase 2a multicenter, open-label, parallel-arm design study to evaluate the safety, tolerability and pharmacodynamics of a single intravitreal injection comparing 2 dose levels of GB-102 on subjects with Diabetic Macular Edema and Retinal Vein Occlusion
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsDiabetic Macular Edema, Retina Vein Occlusion
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
2020202120222023202420252026
First PostedSep 2019
Enrollment StartSep 2019
Primary CompletionJun 2020
TodayJul 2026
First PostedSep 11, 2019
Enrollment StartSep 11, 2019
Primary CompletionJun 5, 2020
TodayJul 2, 2026
Enrollment to primary: 9 monthsPosted 6.8 years ago
Interventions
GB-102drug
Intravitreal injection of GB-102